[1] 秦颖, 张同先, 张巍, 等. 青年乳腺癌临床病理特点分子分型及预后分析[J]. 中国肿瘤临床, 2014, 41(4): 231236. DOI: 10.3969/j.issn.10008179.20131636.
[2] 王承正, 袁鹏, 杨晗昭, 等. AR在不同类型乳腺癌中的表达及临床意义[J]. 河南医学研究, 2015, 24(8): 5456. DOI: 10.3969/j.issn.1004437X.2015.08.025.
[3] 张静, 牛昀, 于琦, 等. AR在不同ER状态乳腺癌中的表达及临床病理意义[J]. 中国肿瘤临床, 2012, 39(3): 131135. DOI: 10.3969/j.issn.10008179.2012.03.003.
[4] Thike AA, YongZheng Chong L, Cheok PY, et al. Loss of androgen receptor expression predicts early recurrence in triplenegative and basallike breast cancer[J]. Mod Pathol, 2014, 27(3): 352360. DOI: 10.1038/modpathol.2013.145.
[5] Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers[J]. Sci Transl Med, 2015, 7(305): 305ps19. DOI: 10.1126/scitranslmed.aac7531.
[6] McNamara KM, Moore NL, Hickey TE, et al. Complexities of androgen receptor signalling in breast cancer[J]. Endocr Relat Cancer, 2014, 21(4): T161181. DOI: 10.1530/ERC140243.
[7] 庞华靖. 三阴性乳腺癌与雄激素的相关性研究[J]. 国际检验医学杂志, 2015, 36(3): 331333. DOI: 10.3969/j.issn.16734130.2015.03.019.
[8] Cohee AA, Adams RN, Johns SA, et al. Longterm fear of recurrence in young breast cancer survivors and partners[J]. Psychooncology, 2015, In press. DOI: 10.1002/pon.4008.
[9] Mohammadizadeh F, Sajadieh S, Sjjadieh H, et al. Androgen receptor expression and its relationship with clinicopathological parameters in an Iranian population with invasive breast carcinoma[J]. Adv Biomed Res, 2014, 3: 132. DOI: 10.4103/22779175.133260.
[10] McInerney NM, Miller N, Rowan A, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort[J]. Breast Cancer Res Treat, 2010, 121(1): 203210. DOI: 10.1007/s1054900905409.
[11] Alshenawy HA. Prevalence of androgen receptors in invasive breast carcinoma and its relation with estrogen receptor, progesterone receptor and Her2/neu expression[J]. J Egypt Natl Canc Inst, 2012, 24(2): 7783. DOI: 10.1016/j.jnci.2012.04.001.
[12] Wenhui Z, Shuo L, Dabei T, et al. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment[J]. Eur J Endocrinol, 2014, 171(4): 527533. DOI: 10.1530/EJE140278.
[13] Gong Y, Wei W, Wu Y, et al. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance[J]. Cancer, 2014, 120(12): 17751779. DOI: 10.1002/cncr.28667.
[14] Sultana A, Idress R, Naqvi ZA, et al. Expression of the androgen receptor, pAkt, and pPTEN in breast cancer and their potential in prognostication[J]. Transl Oncol, 2014, In press. DOI: 10.1016/j.tranon.2014.04.004.
[15] Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triplenegative breast cancer: clinical significance and prognostic associations[J]. Cancers (Basel), 2014, 6(3): 13511362. DOI: 10.3390/cancers6031351.
[16] Wang Y, Yang H. RE: androgen receptor expression and outcomes in early breast cancer: a systematic review and metaanalysis[J]. J Natl Cancer Inst, 2015, 107(10): pii: djv241. DOI: 10.1093/jnci/djv241.
[17] Micello D, Marando A, Sahnane N, et al. Androgen receptor is frequently expressed in HER2positive, ER/PRnegative breast cancers[J]. Virchows Arch, 2010, 457(4): 467476. DOI: 10.1007/s004280100964y. |